ProPhase Labs Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de ProPhase Labs de 97.4% y 60.9% respectivamente, mientras que el BPA crecerá en un 105.1% al año.

Información clave

69.9%

Tasa de crecimiento de los beneficios

37.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.6%
Tasa de crecimiento de los ingresos	73.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 08

ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely

Mar 23

Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt

Nov 30

As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit

Oct 20

Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Jul 22

ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants

Jun 28

Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More

May 14

ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing

May 06

A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Apr 12

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PRPH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	95	6	N/A	N/A	1
12/31/2025	50	-16	N/A	N/A	1
12/31/2024	15	-24	N/A	N/A	1
6/30/2024	18	-26	-18	-15	N/A
3/31/2024	29	-24	-21	-17	N/A
12/31/2023	44	-17	-15	-11	N/A
9/30/2023	63	-10	-14	-10	N/A
6/30/2023	79	-4	-6	-3	N/A
3/31/2023	94	7	5	9	N/A
12/31/2022	123	18	25	29	N/A
9/30/2022	146	31	21	23	N/A
6/30/2022	131	27	13	15	N/A
3/31/2022	111	18	13	15	N/A
12/31/2021	79	6	-18	-14	N/A
9/30/2021	39	-5	-21	-16	N/A
6/30/2021	33	-2	-16	-11	N/A
3/31/2021	28	0	-16	-11	N/A
12/31/2020	15	-2	-4	-3	N/A
9/30/2020	12	-2	3	4	N/A
6/30/2020	11	-2	3	3	N/A
3/31/2020	9	-3	-2	-2	N/A
12/31/2019	10	-3	-1	-1	N/A
9/30/2019	11	-3	-1	-1	N/A
6/30/2019	11	-4	-2	-2	N/A
3/31/2019	12	-3	-1	-1	N/A
12/31/2018	13	-2	-2	-2	N/A
9/30/2018	13	-1	-3	-3	N/A
6/30/2018	14	-1	-2	-2	N/A
3/31/2018	13	-1	N/A	-6	N/A
12/31/2017	10	-2	N/A	-3	N/A
9/30/2017	6	-3	N/A	-1	N/A
6/30/2017	5	-3	N/A	-1	N/A
3/31/2017	4	-3	N/A	2	N/A
12/31/2016	4	-4	N/A	0	N/A
9/30/2016	-6	-3	N/A	-2	N/A
6/30/2016	-3	-2	N/A	-4	N/A
3/31/2016	-2	-2	N/A	-5	N/A
12/31/2015	3	-2	N/A	-3	N/A
9/30/2015	21	-3	N/A	-4	N/A
6/30/2015	22	-7	N/A	-3	N/A
3/31/2015	22	-8	N/A	-4	N/A
12/31/2014	22	-8	N/A	-3	N/A
9/30/2014	23	-7	N/A	-1	N/A
6/30/2014	24	-2	N/A	-1	N/A
3/31/2014	24	-1	N/A	0	N/A
12/31/2013	25	0	N/A	1	N/A
9/30/2013	25	0	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PRPH siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PRPH siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PRPH siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (60.9% al año) de PRPH crezcan más rápidamente que los del mercado US (8.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (60.9% al año) de PRPH crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PRPH se prevé que sea elevada dentro de 3 años.

ProPhase Labs Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 7.5% to US$18.50

Consensus revenue estimates fall by 16%

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 19%

Price target increased by 13% to US$17.00

Consensus forecasts updated

Recent updates

ProPhase Labs Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5605(c)(2)(A)

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Price target increased to US$14.50

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insufficient new directors

Chairman & CEO exercised options and sold US$1.8m worth of stock

Investor sentiment improved over the past week

Price target decreased to US$13.00

Upcoming dividend of US$0.30 per share

ProPhase Labs: A Stellar Quarter And Another Special Dividend